#1De evolus SCIENTIFIC INVESTOR PRESENTATION EV NOVEMBER 2023#2LOVEVOLUS DISCLOSURES SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS DE This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals related to the market position of our product; the potential market acceptance, demand market size, adoption rate, revenue expectations, future results of our product and related loyalty programs, and timing and results of the company's proposed Phase II clinical trial, the potential performance profile of an extra-strength dose, are forward-looking statements. Forward-looking statements are based on current estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Other factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with the success of the launch of JeuveauⓇ, customer and consumer adoption of the product, competition and market dynamics, the efficiency and operability of our digital platform, the ability to successfully complete the Phase II clinical trial, ability to achieve FDA approval and ultimate commercial acceptability and pricing for an "extra strength" JeuveauⓇ dose, our ability to comply with our settlement agreement with Medytox, and our ability to maintain regulatory approval of JeuveauⓇ and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled "Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 that was filed with the Securities and Exchange Commission on March 8, 2023 and any subsequent filings, each of which is available online at www.sec.gov. All written and verbal forward-looking statements attributable to our Company or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. We may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. The forward-looking statements in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise. You should, therefore, not rely on these forward- looking statements as representing our views as of any date subsequent to the date of this presentation. Certain of the industry, statistical and market data in this presentation was obtained from our own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by third parties. All of the market data used in this presentation involves a number of assumptions and limitations. While we believe that the information from these industry publications, surveys and studies is reliable, the industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors, which could cause results to differ materially from those expressed in the estimates made by third parties and by us. Evolus™, JeuveauⓇ, NuceivaⓇ, EvoluxⓇ, and EvolysseⓇ are five of our trademarks that are used in this presentation. Botox® is a registered trademark of Allergan, Inc. Our financial results are prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). This presentation includes non-GAAP financial measures. Our reconciliations of non- GAAP financial measures to GAAP financial measures are located at the end of this presentation. These non-GAAP financial measures should not be considered as an alternative to GAAP financial measures. 2#3LOVVOLUS 00 au euved 100 pribotulinumtoxinA Jeuveau 100 De prabotulinumtoxinA-xis Jeuveau for Injection UNITS VIAL 100 muscular Use | 1 Single-Cow 83 Designed by Eva gabotulinumtoxinA-xv's jeuveau JEUVEAU ulinumtoxinA Jeuveau for Injection 00 UNITS VIAL Use | 1 Single-Do SCIENCE & CLINICAL OVERVIEW muscular Use | 1 Single-Dose Va 98 Designed by Evolus 100 UNITS VIAL tramuscular Use | 1 Single-Dour 88 Designed be Jeuveau for Injection prabotulinumtoxinA-xvis UNITS VIAL 88 Designed by Evolut 100 For Intramuscular Use | 1 Single-Do 100 UNITS VIAL her eramuscular Use | 1 Single-Dose a Designed by Evolus 3#4LOVVOLUS JEUVEAUⓇ DESIGNED WITH PRECISION 900 KDA PRABOTULINUMTOXINA + + 0.5 MG 0.9 MG HUMAN SERUM ALBUMIN SALT De PURIFICATION METHOD: Crystallization and HiPure™ technology FINISHING METHOD: Vacuum dried A precise product with a tight field of effect¹ Puts control in the hands of the injector Helps provide predictable, consistent and safe outcomes • LOW RATES OF EYELID PTOSIS WITH JEUVEAUⓇ2 DRUG-RELATED EYELID PTOSIS (EV-001)³ JEUVEAUⓇ 1% (2/246) 0% (0/84 DRUG-RELATED EYELID PTOSIS (EV-002)4 Kaminer MS, Cox SE, Fagien S, Kaufman J, Lupo M, Shamban A. Re-examining the optimal use of neuromodulators and the changing landscape: A consensus panel update. J Drugs Dermatol. 2020;19(4 suppl 1):s5-15. Adverse Events Observed in EV-001 and EV-0027,6. Phase 3 randomized, multicenter, double-blind, placebo- controlled US trials 1. 2. 3. Data on file; CSR EV-001, BLA761085. Evolus, Inc., Newport Beach, CA 4. Data on file; CSR EV-002, BLA761085. Evolus, Inc., Newport Beach, CA PLACEBO 1% (3/246) 0% (0/78) BOTOX AND JEUVEAU ARE THE ONLY FDA-APPROVED 900 KDA NEUROTOXINS 4#5LOVVOLUS DESIGNED TO COMPETE CLINICALLY WITH THE MARKET LEADER EUROPEAN & CANADIAN PHASE III STUDY EUROPEAN & CANADIAN GLABELLAR LINE PHASE III STUDY PRIMARY ENDPOINT: NON-INFERIORITY RESPONDER RATE DAY 30 PLACEBO BOTOX® JEUVEAUⓇ All 32.7% 41.9% 37.6% Related 4.1% 14.6% 15.5% 87.2% 82.8% SAFETY PROFILE-ADVERSE EVENTS Drug-Related None Other AEs of Interest Ptosis (drug-related) Eyelid-Jeuveau 1.6%, Botox 0% Eyebrow-Jeuveau 0%, Botox 0% Source: Data from Evolus clinical trial EVB-003 1. Glabellar Line Scale JEUVEAUⓇ n=235 4.2% BOTOX® n=244 PLACEBO n=48 GLS1 = None or mild glabellar wrinkles at max frown investigator assessment 5#6LOVAVO US JEUVEAUⓇ WAS THE FIRST BRAND TO CONDUCT A GLABELLAR LINES PHASE III* HEAD-TO-HEAD STUDY VS. THE MARKET LEADER * European & Canadian study CLINICALLY PROVEN >1-POINT (%) IMPROVEMENT ON THE GLS AT MAXIMUM FROWN BY INVESTIGATOR ASSESSMENT BY VISIT 57.4 54.5 JEUVEAUⓇ BOTOX® 95.1 95.7 95.3 93.9 76.7 73.9 57.8 51.5 De 37.9 34.3 2 DAYS 14 DAYS 30 DAYS 90 DAYS 120 DAYS DAYS POST-TREATMENT 150 DAYS 6#7LOVVOLUS JEUVEAUⓇ IS HIGHLY EFFECTIVE FOR MILLENNIALS >1-POINT (%) IMPROVEMENT ON THE GLS AT MAXIMUM FROWN BY INVESTIGATOR ASSESSMENT BY VISIT 1. 2. POOLED PHASE III POST HOC ANALYSIS¹ Study Findings² • • • JeuveauⓇwell-tolerated in both millennial and non-millennial patients, and highly effective for millennials 100% of millennials achieved greater than 1-pt improvement on Glabellar Line Scale on days 7, 14, and 30 100% of millennials were satisfied or very satisfied with treatment at day 7 and 30 EVB-001, EVB-002, and EVB-003 Phase III data Ogilvie P, Jones DH, Avelar RL, Jonker A, Monroe R, Carruthers J. PrabotulinumtoxinA for Treatment of Millennials With Moderate to Severe Glabellar Lines: Post Hoc Analyses of the Phase III Clinical Study Data. Dermatologic Surgery, June 2022. p=0.089 62.5 51.1 p=0.038 p=0.064 p=0.063 p=0.005 100 100 100 94.8 95.0 90.2 90.8 MILLENNIALS NON-MILLENNIALS p=0.230 76.0 67.2 59.0 p=0.689 40.0 37.5 2 DAYS 7 DAYS 14 DAYS 30 DAYS 90 DAYS 120 DAYS 150 DAYS DAYS POST-TREATMENT n=733 n=/#8LOVVOLUS EVOLYSSE, AN INNOVATIVE TECHNOLOGY THAT COMPLEMENTS THE JEUVEAUⓇBRAND De 8#9LOVVOLUS HIGHLIGHTS A HIGHLY COMPETITIVE FILLER LINE • Evolysse™ - a first-generation cold technology Hyaluronic Acid line · 5 fillers in late-stage clinical development Indications including mid face, nasolabial folds, lips and eyes • In partnership with Symatese, developer of the latest generation of Restylane® products in the U.S. • RAISING 2028 REVENUE OUTLOOK FROM $500M TO $700M Increasing guidance by $200M in 2028 based on product launches in 2025, 2026 and 2027 A HIGHLY CAPITAL EFFICIENT AGREEMENT • Minimal short-term dilution delivering material long-term value accretion • Funded to profitability with $50M Pharmakon tranche • Leverage existing sales force, digital infrastructure, Evolus Rewards and co-branded media 769 D#10LOVVOLUS SYMATESE SCIENCE GENESIS 25+ YEARS IN R&D AND MANUFACTURING OF AESTHETICS & MEDICAL BIOMATERIALS LAUNCHED FIRST 2 PRODUCTS: HEMOTESE® & COLLAPATⓇII MENTOR® PEROUSE PLASTIE BREAST IMPLANTS SOLD TO MENTOR 1997 2003 2004 2007 SYMATESE FOUNDED BY INDUSTRY EXPERTS SYMATESE ENTERED PARTNERSHIP WITH L'ORÉAL L'ORÉAL 2011 LAUNCH OF NEVELIA®, DERMAL REGENERATION MATRIX 2013 2021 De SOLD RIGHTS OF XpresHAN TECHNOLOGYTM/OBTⓇ AND RELATED DERMAL FILLERS TO GALDERMA R&D PARTNERSHIP STRENGTHENED WITH L'ORÉAL ON BIOMATERIALS GALDERMA 10#11LOVVOLUS EVOLYSSET MANUFACTURING FIRST-GENERATION COLD TECHNOLOGY HA BY SYMATESE CROSS-LINKING HA Typical cross-linking: Heat Symatese cross-linking: Cold • • BENEFIT Cross-linking technology that better preserves the hyaluronic acid chain designed for dynamic performance and efficacy Less fragmentation aims to improve safety for the benefit of practitioners and their patients Less BDDE is required to get the same gel dynamics FRAGMENTS BDDE HA COLD TECHNOLOGY D HEAT COLD 11#12LOVEVOLUS EVOLYSSE™ PRODUCT LINE 2026 | LAUNCH 2025 | LAUNCH EVOLYSSE™ HSCULPT MID-FACE VOLUME 2027 | LAUNCH EVOLYSSE™ LIFT NASOLABIAL FOLDS EVOLYSSE™ EYE INFRAORBITAL HOLLOWS EVOLYSSE™ SMOOTH NASOLABIAL FOLDS EVOLYSSE™ LIPS VOLUMIZING AND CONTOURING De 12#13ASIDS. 2023 Annual Meeting November 2-5 Chicago, IL JEUVEAU EXTRA-STRENGTH PHASE II, RANDOMIZED, DOUBLE BLIND, ACTIVE-CONTROLLED, INCREASING DOSE TRIAL STUDY: FINAL TOP LINE RESULTS DE#14LOVVOLUS EVOLUS IS UNIQUELY POSITIONED TO CAPITALIZE ON JEUVEAU® EXTRA STRENGTH ORIGINAL JEUVEAUⓇ 20U DOSE / 0.5ML CONCENTRATION EXTRA STRENGTH JEUVEAU® 40U DOSE / 0.25ML CONCENTRATION Jeu 100 for injection 100 otulinumtoxinA Jeuveau for Injection 100 bulinumtoxinA-nis rabotulinumtoxinA Jeuveau for injection 100 Jeuveau 100 Botulinumtoxin Jeuve 100 euve 100 prabotulinumtoxinA Jeuveau 100% Jeuveau 100 100 FIRST PATIENT ENROLLED ENROLLMENT COMPLETED STUDY INITIATION ACTIVITIES 2022 Use 1 100 100 euve 10 e100 100 100 Uved 100 De STUDY DESIGN Double-blind, single treatment, randomized, controlled, prospective, multi-center Up to 1 year follow up | N=150 Three arms: . • 20U Botox® Cosmetic • 20U JeuveauⓇ 40U "Extra-Strength" JeuveauⓇ Double dose, hyper-concentrated INTERIM RESULTS PRESENTED STUDY COMPLETED 2023 RESULTS PRESENTED 14#15LOVEVOLUS JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY GLABELLAR LINES EV • • Study the safety and duration of effect of prabotulinum at an increased dose for the treatment of moderate to severe glabellar lines • Dose doubled Hyper-concentrated Primary objective Duration of effect, time back to baseline by investigator assessment De 15#16LOVVOLUS • JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY STUDY DESIGN Multi-center, double blind, randomized, active controlled 5 sites • N=150 Three arms, randomization 1:1:1 • 40U Prabotulinum 20U Prabotulinum • 20U Onabotulinum Duration 769 • 1 year, or until return to baseline Study population • Stable healthy adults, min 18 years of age Moderate (GLS=2) to Severe (GLS=3) glabellar lines at max frown Year#17LOVVOLUS JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY BASELINE CHARACTERISTICS PraB E-S 40U N=51 OnaB 20U N=50 PraB 20U N=53 AGE IN YEARS, MEAN (RANGE) 46.8 (20, 69) 47 (25,72) 46.8 (22,72) GENDER FEMALE N (%) MALE N (%) RACE 48 (94.1%) 47 (94.0%) 50 (94.3%) 3 (5.9%) 3 (6.0%) 3 (5.7%) ASIAN 0 (0%) 1(2%) 1 (1.9%) BLACK OR AFRICAN AMERICAN 3 (5.9%) 2 (4%) 3 (5.7%) WHITE 48 (94.1%) 47 (94.0%) 49 (92.5%) De 17#18LOVVOLUS JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY BASELINE CHARACTERISTICS PraB E-S 40U N=51 OnaB 20U N=50 PraB 20U N=53 GLS SCORE AT MAX FROWN BY INVESTIGATOR, N (%) MODERATE 15 (29.4%) 14 (28.0%) 18 (34.0%) SEVERE 36 (70.6%) 36 (72.0%) 35 (66.0%) GLS SCORE AT MAX FROWN BY SUBJECT, N (%) MODERATE 11 (21.6%) 7 (14.0%) 13 (24.5%) SEVERE 40 (78.4%) 43 (86.0%) 40 (75.5%) De 18#19LOVEVOLUS 53 JEUVEAU EXTRA- STRENGTH PHASE II De ADVERSE EVENT SUMMARY PraB ES 40U N=51 OnaB 20U N=50 PraB 20U N=53 # EVENTS (N=36) ALL ADVERSE EVENTS 8 (22.2%) 12 (33.3%) 16 (44.4%) DRUG RELATED ADVERSE EVENTS 3 2 DURATION STUDY SAFETY # SUBJECTS WITH AES (N=26) ADVERSE EVENTS ALL ADVERSE EVENTS 7 (13.7%) 11 (22.0%) 8 (15.1%) DRUG RELATED ADVERSE EVENTS 2 2 3 Drug Related Adverse Events PraB ES 40U-headache, forehead discomfort, eyelid ptosis OnaB 20U-headache, headache • PraB 20 U-headache, headache, vasovagal 19#20LOVAVO US De ADVERSE EVENT SUMMARY PraB ES 40U N=51 OnaB 20U N=50 PraB 20U N=53 SEVERITY OF ADVERSE EVENTS MILD 7 (87.5%) 9 (75.0%) 16 (100%) JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY SAFETY ADVERSE EVENTS EV • MODERATE 1 (12.5%) 3 (25.0%) 0 (0%) SEVERE SERIOUS Adverse Event Severity Number of AE's 36 events Mild: 88.9% Moderate: 11.1% Severe: 0% Serious AE: None 0 0 0 0 0 20 20#21LOVVOLUS DURATION JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY De KAPLAN-MEIER: RETURN TO BASELINE GLABELLAR LINES SCALE AT MAXIMUM FROWN Investigator assessment PERCENT OF PATIENTS (%) 100 80 60 40. 20 0 PRABOTULINUM ES 40U 183 (153, 211) DAYS, 26.1 WEEKS, 6.0 MONTHS PRABOTULINUM 20U 149 (130, 174) DAYS, 21.3 WEEKS, 4.9 MONTHS ONABOTULINUM 20U 148 (121, 174) DAYS, 21.1 WEEKS, 4.9 MONTHS 0 30 60 90 120 150 PRA 40U VS. PRA 20U: HR 1.892, P-VALUE 0.0109 PRA 40U VS. ONA 20U: HR 2.38, P-VALUE 0.0002 180 210 240 270 300 330 DAYS FROM TREATMENT 21#22LOVVOLUS DURATION JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY KAPLAN-MEIER: ≥1 PT IMPROVEMENT GLABELLAR LINE SCALE AT MAXIMUM FROWN Investigator assessment 100 80 PRA 40U VS. PRA 20U: HR 1.892, P-VALUE 0.0109 PRA 40U VS. ONA 20U: HR 2.38, P-VALUE 0.0002 De PERCENT OF PATIENTS (%) 60 40. 20 0 PRABOTULINUM ES 40U 183 (153, 211) DAYS, 26.1 WEEKS, 6.0 MONTHS PRABOTULINUM 20U 149 (130, 174) DAYS, 21.3 WEEKS, 4.9 MONTHS ONABOTULINUM 20U 148 (121, 174) DAYS, 21.1 WEEKS, 4.9 MONTHS 0 30 60 90 120 150 180 210 240 270 300 330 DAYS FROM TREATMENT 22 22#23LOVVOLUS DURATION JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY De KAPLAN-MEIER: GLOBAL AESTHETIC IMPROVEMENT RETURN TO BASELINE (IMPROVED, MUCH IMPROVED) Investigator assessment. PERCENT OF PATIENTS (%) 100- 80 60 40 20 PRABOTULINUM ES 40U 183 (153, 211) DAYS, 26.1 WEEKS, 6.0 MONTHS PRABOTULINUM 20U 149 (130, 174) DAYS, 21.3 WEEKS, 4.9 MONTHS ONABOTULINUM 20U 148 (121, 174) DAYS, 21.1 WEEKS, 4.9 MONTHS 30 60 90 120 (95% CLS]): 150 PRA 40U VS. PRA 20U: HR 2.096, P-VALUE 0.0006 PRA 40U VS. ONA 20U: HR 2.39, P-VALUE 0.0002 180 210 240 270 300 330 DAYS FROM TREATMENT 23#24LOVVOLUS JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY EFFICACY: NONE OR MILD GLABELLAR LINE NONE OR MILD GLABELLAR LINE SCALE AT MAXIMUM FROWN INVESTIGATOR ASSESSMENT SUBJECT ASSESSMENT % Responders ཱ ཞ ཆ ➢ ྴ ¥ ཞ རྨུ ཋ。 100 100 De 90 80 70 No data collected Between Day 2 and Day 30 % Responders 60 50 40 30 ◆ No data collected Between Day 2 and Day 30 20 10 0 0 30 60 90 120 150 Days After Treatment 180 210 240 270 300 330 360 0 30 60 90 120 150 180 210 240 270 300 330 360 Days After Treatment -Ona 20U -Pra 20U -- Pra 40U -Ona 20U -Pra 20U -- Pra 40U STUDY COMPLIANCE Subjects completing study: 94.7% (144/152) Prabot 40U 96.1 (49/51) Prab 20U 92.2% (47/51) Ona 20U 96.0% (48/50) 24#25LOVEVOLUS GLABELLAR LINE SCALE SCORE AT MAXIMUM FROWN NONE OR MILD GLABELLAR LINES AS A RESPONDER DEFINITION THE IMPORTANCE OF BASELINE CHARACTERISTICS RESPONDER NON-RESPONDER 1 PT ![ 2 PT De GLABELLAR LINE SCALE AT MAXIMUM FROWN SCORE SEVERITY DESCRIPTION 0 NO LINES 1 MILD LINES 2 MODERATE LINES 3 SEVERE LINES 25#26COMPARISON: JEUVEAU EXTRA-STRENGTH PHASE II STUDY WITH DAXXIFY PHASE 2/3 SAKURA + BELMONT TRIALS DE#27LOVVOLUS De JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY EFFICACY: NONE OR MILD GLABELLAR LINE RESPONDERS NONE OR MILD GLABELLAR LINES AT MAXIMUM FROWN Investigator + Subject Assessment Pra 40U vs. Daxi 40U Sakura 1 PERCENT OF 90 80 70 60 50 40 ཤྲཱ ཞ ༅ ➢ ཋ ཞ ¥ ཞ 8 ཋ 100 RESPONDERS (%) * 20 Prabot Prabot Daxi - Daxi 40U 40U 40U 40U 10 (IA) (SA) (IA) (SA) 0 0 30 60 60 90 06 120 150 ◆ No prabot data collected between Day 2 and Day 30 *DaxxifyⓇ FDA Prescribing Information (Graph GL1) Carruthers, Plastic Reconstructive Surgery 2020 Jan; 145 (1): 45-58 Note: Results drawn from multiple studies. Caution should be used when interpreting cross-study comparisons Baseline Demographics Daxibotulinum Sakura 163.2 Moderate Prabotulinum 40U PII 70.6% Severe 1pt change required 2 pt change required 180 210 240 270 300 330 360 DAYS AFTER TREATMENT 22 27#28LOVVOLUS De JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY EFFICACY: NONE OR MILD GLABELLAR LINE RESPONDERS NONE OR MILD GLABELLAR LINES AT MAXIMUM FROWN Investigator + Subject Assessment Pra 40U vs. Daxi 40U Sakura 2 PERCENT OF 90 80 70 60 50 40 g ཞ ཧྨ ➢ ཋ ྴ ༄ ཞ 8 ཤྐ 100 RESPONDERS (%) 30 * 20 Prabot Prabot Daxi Daxi 40U 40U 40U 40U 10 (IA) (SA) (IA) (SA) 0 0 30 60 00 90 120 150 ◆ No prabot data collected between Day 2 and Day 30 *DaxxifyⓇ FDA Prescribing Information (Graph GL1) Carruthers, Plastic Reconstructive Surgery 2020 Jan; 145 (1): 45-58 Note: Results drawn from multiple studies. Caution should be used when interpreting cross-study comparisons Baseline Demographics Daxibotulinum Sakura 163.2 Moderate Prabotulinum 40U PII 70.6% Severe 1pt change required 2 pt change required 180 210 240 270 300 330 360 DAYS AFTER TREATMENT 28#29LOVVOLUS FDA GUIDANCE FOR INDUSTRY UPPER FACIAL LINES: DEVELOPING BOTULINUM TOXIN DRUG PRODUCTS AUGUST 2014 EFFICACY ENDPOINTS Success should be defined as achievement of a score of 0 or 1 and a two- grade improvement from the baseline, on both the IA and the SSA scales concurrently, to ensure clinical significance. Because it may be possible to move to an adjacent category on the assessment scale with only a small level of improvement, a one-grade change may not represent a clinically meaningful intrasubject change. Sponsors should evaluate duration of effect with a clinically and statistically meaningful approach. Assessment measures for duration of effect should be the same as for the primary efficacy endpoint. Assessment of the duration of effect should reflect the time period for which a clinically meaningful proportion of subjects maintain response. 769 D#30LOVVOLUS De JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY EFFICACY: GLABELLAR LINE SCALE COMPOSITE SCORE NONE OR MILD AT MAXIMUM FROWN AND ≥ 2-POINT IMPROVEMENT Investigator + Subject Assessment (FDA Composite Score) PERCENT OF RESPONDERS 100 5 N WB · ŏ ∞ g 40 60 70 80 90 (%) 50 0 0 30 60 60 ◆No prabot data collected between Day 2 and Day 30 *DaxxifyⓇ FDA Prescribing Information (Graph GL1) Carruthers, Plastic Reconstructive Surgery 2020 Jan; 145 (1): 45-58 Note: Results drawn from multiple studies. Caution should be used when interpreting cross-study comparisons Prabot 40U Phase II Daxi 40U Daxi 40U - Sakura 1 Sakura 2 90 120 150 180 210 240 270 DAYS AFTER TREATMENT 30 50#31LOVEVOLUS JEUVEAU EXTRA- STRENGTH PHASE II DURATION STUDY SUMMARY SAFETY Profile similar across the groups. • . • 88.9% of AE's mild, 11% moderate No serious adverse events DURATION Time to return to baseline among multiple parameters was 26 weeks or 6 months De 31#32THANK YOU